Report Company Directory

OSINO RESOURCES CORP.

• Equity Metals Corporation (TSXV: EQTY / OTCQB: EQMEF) – Drilling Expands Resources by at Least 30% by Fundamental Research
• Contango Ore Inc. (NYSE: CTGO) – Aiming to Commence Production in Q3 by Fundamental Research
• Western Exploration Inc. (TSXV: WEX / OTC: WEXPF) – Positive Drill Results Signal Resource Expansion Potential by Fundamental Research
• Loncor Gold Inc. (TSX: LN / OTCQX: LONCF / FSE: LO51) – Well Positioned Amidst Rising M&A in Junior Gold – Reinitiating Coverage by Fundamental Research

OSIRIS ACQUISITION CORP

• Hybridan Small Cap Feast - 18 Jul 23 by Hybridan
• Hybridan Small Cap Feast - 23 Mar 23 by Hybridan

OSIRIS CORP

Osiris Therapeutics

• Osiris Therapeutics, Inc. Announces Closing of Acquisition by Smith & Nephew plc by GlobeNewsWire
• Osiris Therapeutics, Inc. Enters Agreement to be Acquired by Smith & Nephew plc by GlobeNewsWire
• Osiris Therapeutics, Inc. Appoints Samson Tom, PhD, MBA to Serve as President and Chief Executive Officer by GlobeNewsWire
• Osiris Therapeutics, Inc Reports Third Quarter 2018 Results by GlobeNewsWire
• Osiris Therapeutics, Inc. to Present Advanced Clinical and Scientific Abstracts at Symposium on Advanced Wound Care (SAWC) Fall Meeting, November 2-4, 2018, in Las Vegas, Nevada by GlobeNewsWire
• Osiris Therapeutics, Inc. Announces Peer-Reviewed Publication Demonstrating That Lyopreservation Method Developed for Living Tissues is an Alternative to Cryopreservation with the Convenience of Ambient Storage by GlobeNewsWire
• Osiris Therapeutics, Inc. Announces GrafixPL PRIMEâ„¢ Launches October 1, 2018 by GlobeNewsWire
• Osiris Therapeutics, Inc. Announces Peer-Reviewed Publication Comparing the Efficacy of Viable Cryopreserved Placental Membranes to Human Fibroblast-Derived Dermal Substitute in the Treatment of Chronic Diabetic Foot Ulcers (DFUs) in a Multicenter Randomi by GlobeNewsWire
• Osiris Therapeutics, Inc. to Re-list on The Nasdaq Global Market on August 1, 2018 by GlobeNewsWire
• Osiris Announces Enrollment of Patients in a Clinical Trial Evaluating GrafixPL PRIMEâ„¢ in the Treatment of Chronic Venous Leg Ulcers by GlobeNewsWire

Osirium Technologies

• Osirium Technologies - Termination of coverage by Edison Investment Research
• Osirium Technologies - Accelerating bookings by Edison Investment Research
• Osirium Technologies - Positive Q1 update by Edison Investment Research
• Osirium Technologies - Improving bookings outlook by Edison Investment Research
• Osirium Technologies - FY21 in line by Edison Investment Research
• Osirium Technologies - Trimming FY21 expectations by Edison Investment Research
• Osirium Technologies - Trimming FY21 expectations by Edison Investment Research
• Osirium Technologies - Accelerating customer wins by Edison Investment Research
• Osirium Technologies - Accelerating customer wins by Edison Investment Research
• Monthly LMI Update Independent Investment Research by Independent Investment Research